Fed’s Powell opens door to potential rate cuts at Jackson Hole
Brian Goff, the Chief Executive Officer of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), recently executed several stock transactions involving the company’s common stock. On March 3, Goff sold a total of 12,947 shares at a price of $35.54 each, amounting to approximately $460,135. These sales were conducted to cover tax obligations associated with the vesting of performance share units. Following these transactions, Goff holds 92,345 shares directly. According to InvestingPro data, AGIO’s stock has experienced significant price movement recently, currently trading at $33.39, with analysts setting price targets ranging from $43 to $74.
In addition, on March 1, Goff acquired 26,500 shares through the exercise of restricted stock units, which were executed at no cost. The transactions reflect routine adjustments to Goff’s stock holdings, as per the company’s stock unit agreements. InvestingPro analysis shows the company maintains a strong financial position with a "GOOD" overall health score and an impressive current ratio of 11.9, indicating robust liquidity. Discover more insights about AGIO and access comprehensive analysis of 1,400+ stocks with an InvestingPro subscription.
In other recent news, Agios Pharmaceuticals reported its fourth-quarter 2024 earnings, surpassing analysts’ expectations with an earnings per share (EPS) of -$1.44 compared to the forecast of -$1.68. The company also achieved revenue of $10.7 million, exceeding the projected $9.32 million. Agios ended the quarter with a strong cash position of $1.5 billion, indicating robust financial health. Additionally, H.C. Wainwright initiated coverage on Agios Pharmaceuticals with a Buy rating and set a price target of $58. The firm’s analyst, Emily Bodnar, expressed optimism about Agios’s lead asset, mitapivat, particularly for its potential label expansion into thalassemia and sickle cell disease by 2026. The RISE UP study’s Phase 2 data in sickle cell disease have shown promising results, with significant increases in hemoglobin levels. Agios’s mitapivat is currently the only therapy in development for thalassemia that has demonstrated efficacy across all subtypes. These developments reflect Agios’s strategic focus on expanding its product pipeline and maximizing its Pyrakind franchise.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.